GeoVax Labs, Inc. (Nasdaq: GOVX) today highlighted the strong alignment between its GEO-MVA vaccine platform strategy and the priorities outlined in the U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response's (ASPR) newly released Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Multiyear Budget: Fiscal Years 2025–2029. The report provides the federal government's five-year roadmap for investments in medical countermeasures, advanced manufacturing, Strategic National Stockpile (SNS) modernization, and preparedness against emerging infectious disease and biological threats.
According to the report, approximately 65% of future medical countermeasure investment is expected to focus on threat-agnostic and multi-threat technologies, while emphasizing domestic manufacturing capability, scalable vaccine platforms, and sustained preparedness infrastructure. The report also projects a total five-year medical countermeasure investment need of approximately $66.9 billion, underscoring the growing strategic importance of resilient domestic biodefense capabilities.
"The release of ASPR's five-year preparedness strategy reinforces many of the strategic priorities that have guided our GEO-MVA program," said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. "The report recognizes that future preparedness requires more than individual vaccines - it requires flexible platform technologies, domestic manufacturing capability, resilient supply chains, and sustainable medical countermeasure infrastructure. GEO-MVA has been developed with these national priorities in mind."
GeoVax believes several priorities identified in the ASPR strategy directly support the long-term strategic rationale underlying the GEO-MVA program. The ASPR report identifies sustaining and expanding domestic commercial manufacturing capability as one of the nation's principal preparedness challenges. GeoVax's GEO-MVA program is designed to establish a U.S.-based source of Modified Vaccinia Ankara (MVA) vaccine manufacturing, supporting domestic supply-chain resilience while reducing dependence on limited global manufacturing capacity.
The report also emphasizes investments in threat-agnostic and multi-threat technologies capable of responding rapidly to future public health emergencies. The MVA vector represents a well-established vaccine platform with demonstrated applicability across multiple infectious disease targets, providing flexibility beyond any single indication. Additionally, the ASPR strategy calls for continued modernization of the Strategic National Stockpile while addressing lifecycle management, replenishment, and transition of new medical countermeasures into long-term preparedness programs. GeoVax believes the GEO-MVA program aligns with these objectives by supporting future U.S. preparedness capacity for orthopoxvirus threats.
The report identifies emerging infectious diseases as among the nation's highest preparedness priorities while emphasizing investments that enable rapid response to evolving threats. GeoVax's clinical development strategy for GEO-MVA is intended to support preparedness against mpox and smallpox while leveraging the broader capabilities of the MVA platform.
The ASPR report reflects a continuing evolution in federal preparedness strategy - from investing primarily in individual products toward investing in strategic capabilities, including manufacturing infrastructure, platform technologies, and sustainable preparedness systems. GeoVax believes these evolving priorities reinforce the long-term strategic value of domestic vaccine manufacturing capabilities that can support future public health emergency response.
"Preparedness is increasingly being viewed as a strategic national capability rather than simply a collection of products," added Mr. Dodd. "We believe this evolution supports the importance of maintaining flexible vaccine platforms and domestic manufacturing infrastructure capable of responding to future biological threats."
GEO-MVA is GeoVax's Modified Vaccinia Ankara (MVA) vaccine candidate being developed to support protection against mpox and smallpox. The program is advancing through an immunobridging regulatory strategy following positive Scientific Advice from the European Medicines Agency (EMA) and is intended to provide an additional source of MVA vaccine manufacturing capacity supporting future public health preparedness initiatives. GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. For more information, visit www.geovax.com.
